102 related articles for article (PubMed ID: 2628073)
1. Methotrexate increases the activation and cytotoxicity of 5-fluorouracil: detected by 19F n.m.r. in vivo.
McSheehy PM; Prior MJ; Griffiths JR
Biochem Soc Trans; 1989 Dec; 17(6):1050. PubMed ID: 2628073
[No Abstract] [Full Text] [Related]
2. Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo.
McSheehy PM; Prior MJ; Griffiths JR
Br J Cancer; 1992 Mar; 65(3):369-75. PubMed ID: 1558790
[TBL] [Abstract][Full Text] [Related]
3. In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy.
el-Tahtawy A; Wolf W
Cancer Res; 1991 Nov; 51(21):5806-12. PubMed ID: 1933851
[TBL] [Abstract][Full Text] [Related]
4. [Experimental toxicologic and therapeutic studies on the activity of the CMF(cyclophosphamide-methotrexate-5-fluorouracil) scheme versus the VMF(vincristine-methotrexate-5-fluorouracil) scheme].
Berger MR; Habs M; Schmähl D
Arch Geschwulstforsch; 1984; 54(4):263-78. PubMed ID: 6548622
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by 19F-magnetic resonance spectroscopy.
Katzir I; Shani J; Wolf W; Chatterjee-Parti S; Berman E
Cancer Invest; 2000; 18(1):20-7. PubMed ID: 10701363
[TBL] [Abstract][Full Text] [Related]
6. Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo.
McSheehy PM; Prior MJ; Griffiths JR
Br J Cancer; 1989 Sep; 60(3):303-9. PubMed ID: 2789936
[TBL] [Abstract][Full Text] [Related]
7. [Preclinical and clinical studies of sequential therapy with methotrexate and 5 fluorouracil in breast cancer].
Kitamura M; Tominaga T; Hayashi K; Takahashi I; Kosaki G
Nihon Gan Chiryo Gakkai Shi; 1986 Dec; 21(10):2430-8. PubMed ID: 3572145
[No Abstract] [Full Text] [Related]
8. In vivo 31P MRS in new antineoplastic agents evaluation on experimental tumor models.
Le Moyec L; Naruse S; Higuchi T; Hirakawa K; Watari H; de Certaines JD; Roques BP
Cancer Biochem Biophys; 1988 Jul; 10(1):31-45. PubMed ID: 2465078
[TBL] [Abstract][Full Text] [Related]
9. [Characteristics of growth and sensitivity to cytostatics of Walker 256 carcinosarcoma in randombred and Wistar rats].
Karaivanova MK
Eksp Med Morfol; 1974; 13(4):237-42. PubMed ID: 4219353
[No Abstract] [Full Text] [Related]
10. Chemotherapy of experimental meningeal carcinomatosis.
Ushio Y; Posner JB; Shapiro WR
Cancer Res; 1977 Apr; 37(4):1232-7. PubMed ID: 844048
[No Abstract] [Full Text] [Related]
11. Tumor uptake of 5-fluorouracil, methotrexate, and adriamycin vs gallium.
Webber MM; Verma R; Chang B
Int J Rad Appl Instrum B; 1986; 13(6):625-7. PubMed ID: 3470274
[TBL] [Abstract][Full Text] [Related]
12. Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics.
Presant CA; Wolf W; Albright MJ; Servis KL; Ring R; Atkinson D; Ong RL; Wiseman C; King M; Blayney D
J Clin Oncol; 1990 Nov; 8(11):1868-73. PubMed ID: 2230874
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of 5-fluorouracil antitumor effects by the prior administration of methotrexate.
Damon LE; Cadman E; Benz C
Pharmacol Ther; 1989; 43(2):155-85. PubMed ID: 2675132
[No Abstract] [Full Text] [Related]
14. [Studies in vivo and in vitro on the influence of 5-fluorouracil and n'-(2'-furanidyl)-5-fluorouracil on the walker carcinosarcoma 256 in the rat (author's transl)].
Mattern J; Volm M; Wayss K; Weber N
Arzneimittelforschung; 1980; 30(6):981-4. PubMed ID: 6774738
[TBL] [Abstract][Full Text] [Related]
15. [Clinical application of sequential dose methotrexate and 5-FU as a neoadjuvant chemotherapy in advanced stomach carcinoma].
Urabe T; Akazawa S; Suda Y; Minaguchi S; Yoshida S
Nihon Gan Chiryo Gakkai Shi; 1986 Oct; 21(9):2284-95. PubMed ID: 3819553
[No Abstract] [Full Text] [Related]
16. Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits.
Wolf W; Presant CA; Servis KL; el-Tahtawy A; Albright MJ; Barker PB; Ring R; Atkinson D; Ong R; King M
Proc Natl Acad Sci U S A; 1990 Jan; 87(1):492-6. PubMed ID: 2296605
[TBL] [Abstract][Full Text] [Related]
17. Development of an in vivo 19F magnetic resonance method for measuring oxygen deficiency in tumors.
Raleigh JA; Franko AJ; Kelly DA; Trimble LA; Allen PS
Magn Reson Med; 1991 Dec; 22(2):451-66. PubMed ID: 1812379
[TBL] [Abstract][Full Text] [Related]
18. Hyperthermia plus methotrexate combination modality treatment in transplanted Walker sarcoma.
Kosmidis P; Uzunoglou N; Elemenoglou J; Kottaridis S
Chemioterapia; 1987 Jun; 6(2 Suppl):690-1. PubMed ID: 3509524
[No Abstract] [Full Text] [Related]
19. Biochemical modulation of 5-fluorouracil with methotrexate in advanced colorectal cancer patients pretreated with adjuvant 5-fluorouracil and leucovorin.
Pronzato P; Vaira F; Vigani A; Losardo P; Bertelli G
Anticancer Res; 1995; 15(6B):2679-82. PubMed ID: 8669846
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of solid-tumor chemotherapy by metabolic alteration.
Meyer JA
Ann Surg; 1974 Jan; 179(1):88-93. PubMed ID: 4544742
[No Abstract] [Full Text] [Related]
[Next] [New Search]
